ARC 521

Drug Profile

ARC 521

Alternative Names: ARC-521

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Roche Madison
  • Developer Arrowhead Pharmaceuticals
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action Hepatitis B virus replication inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 29 Nov 2016 Discontinued - Phase-I/II for Hepatitis B in New Zealand (Parenteral) due to company shifting its focus on the development of RNAi therapeutics utilising its subcutaneous and extra-hepatic delivery systems
  • 09 Jun 2016 Phase-I/II clinical trials in Hepatitis B in New Zealand (Parenteral)
  • 28 Apr 2016 Arrowhead files an IND application with the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) in New Zealand for Hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top